Stephen Ray Mitchell Sells 5,000 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the sale, the director now owns 44,857 shares of the company’s stock, valued at $231,910.69. This trade represents a 10.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Vanda Pharmaceuticals Trading Down 1.2 %

Shares of NASDAQ VNDA opened at $4.92 on Wednesday. The stock has a market cap of $286.89 million, a P/E ratio of -17.57 and a beta of 0.77. The business’s fifty day simple moving average is $4.80 and its 200-day simple moving average is $5.27. Vanda Pharmaceuticals Inc. has a 12-month low of $3.44 and a 12-month high of $6.75.

Analyst Upgrades and Downgrades

VNDA has been the subject of a number of research reports. Cantor Fitzgerald lifted their price objective on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. StockNews.com assumed coverage on Vanda Pharmaceuticals in a research report on Sunday. They issued a “hold” rating for the company. Finally, HC Wainwright started coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, October 31st. They set a “buy” rating and a $18.00 price target on the stock.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several large investors have recently bought and sold shares of VNDA. Meeder Asset Management Inc. acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth about $39,000. ORG Wealth Partners LLC acquired a new position in Vanda Pharmaceuticals during the 3rd quarter worth approximately $40,000. China Universal Asset Management Co. Ltd. increased its position in shares of Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 4,374 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter valued at $61,000. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Vanda Pharmaceuticals by 18.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 2,425 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.